Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SanBio Co ( (JP:4592) ) has provided an update.
SanBio Co., Ltd. reported non-operating expenses and deferred income taxes for the first quarter of the fiscal year ending January 31, 2026. The company recorded a foreign exchange loss of 711 million yen and a foreign currency translation adjustment of 651 million yen due to exchange rate fluctuations. Additionally, 23 million yen was recorded in stock issuance expenses, and deferred income taxes of negative 219 million yen were recognized. These financial activities reflect the company’s ongoing financial management and could impact its earnings performance.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on regenerative medicine and cell therapy products. The company is known for its innovative treatments targeting neurological disorders and aims to expand its market presence in the healthcare sector.
Average Trading Volume: 5,613,796
Technical Sentiment Signal: Buy
Current Market Cap: Yen265B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.